Sugi Predict

Sugi Predict / Targets / RUNX1

RUNX1

Runt-related transcription factor 1 · Q01196 · RUNX1 on Sugi Atlas →

6,694 patent compounds predicted against RUNX1, 4,186 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL179106 SCHEMBL179106 0.57 12/20
SCHEMBL179114 SCHEMBL179114 0.59 11/20
SCHEMBL902354 SCHEMBL902354 0.63 10/20
SCHEMBL126350 SCHEMBL126350 0.54 9/20
SCHEMBL179101 SCHEMBL179101 0.61 7/20
SCHEMBL179102 SCHEMBL179102 0.59 7/20
SCHEMBL179096 SCHEMBL179096 0.58 7/20
SCHEMBL2108297 SCHEMBL2108297 0.56 7/20
SCHEMBL179099 SCHEMBL179099 0.47 6/20
SCHEMBL179143 SCHEMBL179143 0.81 4/20
SCHEMBL179112 SCHEMBL179112 0.56 4/20
SCHEMBL2722588 SCHEMBL2722588 0.51 4/20
SCHEMBL179108 SCHEMBL179108 0.51 4/20
SCHEMBL1266231 SCHEMBL1266231 0.48 4/20
SCHEMBL125214 SCHEMBL125214 0.45 4/20
SCHEMBL834587 SCHEMBL834587 0.52 3/20
SCHEMBL179148 SCHEMBL179148 0.50 3/20
SCHEMBL179105 SCHEMBL179105 0.48 3/20
SCHEMBL179144 SCHEMBL179144 0.48 3/20
SCHEMBL179145 SCHEMBL179145 0.48 3/20

Clinical trials — most relevant to RUNX1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) PHASE3COMPLETED
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia PHASE3COMPLETED
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia PHASE3COMPLETED
Timed-Sequential Induction in CBF-AML PHASE3COMPLETED
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT PHASE2RECRUITING
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, 7+3) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) PHASE2RECRUITING
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers PHASE2NOT_YET_RECRUITING
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder PHASE2ACTIVE_NOT_RECRUITING
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. PHASE2COMPLETED
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML PHASE2UNKNOWN
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE2COMPLETED
The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma PHASE2UNKNOWN
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia PHASE1/PHASE2RECRUITING
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients PHASE2RECRUITING
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder PHASE1RECRUITING
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission? EARLY_PHASE1UNKNOWN
Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) nanUNKNOWN
Haplo-Cord HSCT for AML/MDS nanRECRUITING
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis nanRECRUITING
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients nanUNKNOWN
Longitudinal Studies of Patient With FPDMM nanRECRUITING
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia nanCOMPLETED
Natural History Study of GATA2 Deficiency and Related Disorders nanRECRUITING
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RUNX1 binder may also engage these)

ProteinNameSimilarity
Q6PF39 — 1.000 Q6PF39 →
Q03347 — 1.000 Q03347 →
Q63046 — 1.000 Q63046 →
Q13950 — 0.998 Q13950 →
Q13761 — 0.997 Q13761 →
Q5RFT9 — 0.995 Q5RFT9 →
Q08775 — 0.995 Q08775 →
Q4WXK4 — 0.995 Q4WXK4 →
Q4WYQ4 — 0.994 Q4WYQ4 →
Q1K8E7 — 0.994 Q1K8E7 →
P43692 — 0.994 P43692 →
P43696 — 0.994 P43696 →
P97767 — 0.994 P97767 →
Q8NEA6 — 0.994 Q8NEA6 →
A0A194W8T8 — 0.993 A0A194W8T8 →
Q64131 — 0.993 Q64131 →
O13415 — 0.993 O13415 →
Q91678 — 0.993 Q91678 →
P56721 — 0.993 P56721 →
Q96MY1 — 0.993 Q96MY1 →
O74308 — 0.992 O74308 →
Q1HVC7 — 0.992 Q1HVC7 →
Q91660 — 0.992 Q91660 →
P03234 — 0.992 P03234 →
Q6GZQ5 — 0.992 Q6GZQ5 →
Q5IS56 — 0.992 Q5IS56 →
Q92259 — 0.992 Q92259 →
Q10328 — 0.992 Q10328 →
P43691 — 0.992 P43691 →
Q9XSB7 — 0.991 Q9XSB7 →